小鼠组织中肝靶向前药5-氟尿嘧啶含量的高效液相色谱法测定

以5-溴尿嘧啶为内标,建立了高效液相色谱法测定小鼠组织中肝靶向前药(半乳糖化人血清白蛋白与5-氟尿嘧啶偶联物)中5-氟尿嘧啶(5-FU)含量的分析方法.样品经盐酸水解、乙酸乙酯提取、离心后,取上清液在40 ℃下用N2吹干,用流动相溶解、定容后进样分析.色谱条件:安捷伦Hypersil C18色谱柱(4.0 mm×250 mm, 5 μm),流动相为甲醇-磷酸缓冲溶液,流速0.7 mL/min,UV检测波长为270 nm.方法的线性范围为1 ～20 mg/L,检出限(S/N=3)为0.1 mg/L,回收率为93% ～104%.该法操作简便、灵敏度高,适于组织中肝靶向前药半乳糖化人血清白蛋白与5-氟尿嘧啶偶联物(Gal-HSA-5-FU)的5-FU含量测定.     

氨基酸5-氟尿嘧啶酯类衍生物的合成及其抗肿瘤活性研究

以N-保护的氨基酸钾盐与1-(ω-溴丙基)-5-氟尿嘧啶和1-(ω-溴丁基)-5-氟尿嘧啶反应,制备了18种氨基酸的ω-(N¹-5-氟尿嘧啶基)-丙醇酯和丁醇酯的盐酸盐,并确定了它们的结构。动物试验的初步结果表明,酪氨酸、苯丙氨酸的3-(N¹-5-氟尿嘧啶基)-丙醇酯盐酸盐对小鼠艾氏腹水癌的抑制率分别为88.1%和86.7%。     

新型氯苯基卟啉-5-氟尿嘧啶的合成

以3,4-二氯苯甲醛、对羟基苯甲醛,吡咯和1,5-二溴戊烷(或1,6-二溴己烷)为原料,经两步反应合成了溴烷氧基氯苯基卟啉(2a或2b);2与5-氟尿嘧啶反应,合成了两种新型的氯代苯基卟啉-5-氟尿嘧啶[1a(产率28.26%)和1b(产率29.34%)],其结构经UV-Vis,~1H NMR,IR和MS表征.     

超高效液相色谱-四极杆飞行时间质谱法测定大鼠血浆中的N6-羟苄腺苷北大核心CSCD

建立了测定大鼠血浆中N6-羟苄腺苷的超高效液相色谱-四极杆飞行时间质谱(UPLC-QTOF-MS)分析方法,并应用于N6-羟苄腺苷药代动力学研究。采用Agilent ZORBAX SB-C18色谱柱(150 mm×3 mm,1.8μm)对目标物分离,以0.2%(v/v)甲酸水溶液和乙腈为流动相进行梯度洗脱;以6-苄氨基嘌呤作为内标,在电喷雾离子源正离子模式下进行定量分析。结果表明:N6-羟苄腺苷在0.625~160 ng/mL的范围内线性关系良好(r>0.99);方法的回收率在88.41%~108.26%之间;检出限达到0.1 ng/mL;日内和日间准确度(以RE计,RE=(测定浓度-加标浓度)/加标浓度×100%)均在±15%之内,精密度(以RSD计)均小于6%。该方法选择性好,灵敏度高,重现性好,结果准确,可用于N6-羟苄腺苷的血药浓度监测及药代动力学研究。     

高效液相色谱法同时测定人血清中5-氟尿嘧啶及其代谢物5-脱氧尿苷

5-氟尿嘧啶(5-fluorouracil,5-FU)是治疗消化道恶性肿瘤的首选药,为探讨其最佳给药方案,本文利用高效液相色谱(HPLC)建立了同时测定人血清中5-FU及其活性代谢物5-脱氧尿苷(5-fluoro-2′-     

5-氟尿嘧啶-聚[N-(2-羟乙基)-L-谷酰胺]的合成及缓释性能研究

以聚谷氨酸苄酯为原料,用乙醇胺进行胺解得水溶性的可生物降解的聚[N-(2-羟乙基)-L-谷酰胺];用光气/甲苯液活化5-氟尿嘧啶,将其以共价键形式键合在高分子上,得5-氟尿嘧啶的高分子前药。用IR、UV、1HNMR及DSC对其结构进行表征,用紫外光谱测定其药物含量,载药高分子的接药率约为38.4%,高分子前药在pH=7.2的磷酸盐介质中42天内的药物累积释放量为57.53%。实验结果表明,5-氟尿嘧啶以共价键的形式键合在聚[N-(2-羟乙基)-L-谷酰胺]之上,在体外有明显的缓释效果。     

测定兔血清中氟尿嘧啶的高效液相色谱法

改进了血清中氟尿嘧啶的液相色谱分析方法 ,采用DiamonsilC18150mm×4.6mm×5μm分析柱 ,ODS50mm×4.6mm×10μm为保护柱 ,UV检测波长为270nm ,甲醇 -水(体积比3∶97 ,冰醋酸调pH=3.5)为流动相 ,流速0.5mL·min-1,外标法定量 ;以乙酸乙酯萃取血浆样品 ;氟尿嘧啶在0.17～42.50mg·L-1 范围内线性良好 ,日间RSD(n=5)为1.9%～2.3 %,日内RSD(n=5)为0.9 %～1.0 % ,方法回收率为92 % ;该法准确 ,适用于氟尿嘧啶常规监测及药代动力学研究     

四(5-氟尿嘧啶-1-基乙酰氧基苯基）卟啉及其锌配合物的合成

以二环己基碳二亚胺为脱水剂,meso-四(对羟基苯基)卟啉与5-氟尿嘧啶-1-基乙酸反应,合成了一种新型meso-四[4-(5-氟尿嘧啶-1-基乙酰氧基)苯基]卟啉化合物(A),产率12.7%;将其与乙酸锌反应得到其锌配合物(B),产率30.8%。 通过1H NMR、IR、MS、UV-Vis及元素分析确证了卟啉化合物A及其锌配合物B的结构。     

5-氟尿嘧啶修饰卟啉的合成及抗肿瘤活性

合成了一种5-氟尿嘧啶修饰的自由卟啉(5-[2-(5-氟尿嘧啶-3-基)乙氧基苯基]-10,15,20-三(4-甲氧基苯基)卟啉)及其2种金属卟啉配合物:5-[2-(5-氟尿嘧啶-3-基)乙氧基苯基]-10,15,20-三(4-甲氧基苯基)锰卟啉和5-[2-(5-氟尿嘧啶-3-基)乙氧基苯基]-10,15,20-三(4-甲氧基苯基)锌卟啉。 通过紫外可见光谱(UV-Vis)、红外光谱(IR)和核磁共振谱氢谱(¹H NMR)对目标化合物进行了结构表征。 用噻唑蓝法(MTT法)测定了自由卟啉、锰卟啉及锌卟啉分别对肺腺癌细胞株A549、肝癌细胞株Bel7402和人结肠癌细胞株HCT-8的抑制活性。 其中,锰卟啉对人结肠癌细胞株HCT-8的半抑制浓度为IC₅₀为17.8 mg/L,具有一定的细胞毒作用。     

氟尿嘧啶-壳寡糖/硒纳米微球的制备及抑制肿瘤细胞生长活性

为研究抗肿瘤药物与辅药负载于同一药物载体的作用效果, 首先以壳寡糖和广谱抗肿瘤药物5-氟尿嘧啶(5-Fu)为原料通过化学键合合成氟尿嘧啶-壳寡糖前体, 然后以其为模板通过溶胶-凝胶法制备了同时负载氟尿嘧啶和硒纳米颗粒的壳寡糖微球. 采用透射电子显微镜(TEM)、 Zeta电位仪和红外光谱(IR)对制备的微球进行了表征, 结果表明, 微球粒径为433 nm, 硒纳米颗粒包裹在微球内; 对微球包裹药物进行检测发现, 5-Fu装载率为(8.2±0.3)%, 硒装载率为(7.96±0.34)%; 体外缓释检测和细胞实验结果证实, 微球能够缓慢释放2种药物, 其缓释作用能很好地抑制肝癌细胞SMMC-7721的生长.     

HPLC determination and pharmacokinetic studies of salvianolic acid B in rat plasma after oral administration of Radix Salviae Miltiorrhizae extract

A precise and reproducible HPLC method has been established and validated for determination of salvianolic acid B (SalB) in rat plasma after oral administration of Radix Salviae Miltiorrhizae extract. Liquid-liquid extraction was adopted for the sample preparation. Separation was accomplished on a C(18) column with a linear gradient elution consisting of acetonitrile and aqueous phosphoric acid. Ultraviolet detection was at 280 nm. The method was validated over the concentration range 10.8-259.4 microg/mL using 1 mL of plasma. The assay was linear over this concentration range with a coefficient of variation less than 7%. The extraction recovery of SalB was within the range 71-83% with RSD 11%. The mean recovery of the internal standard was 84% (n = 6) with RSD of 5.6%. This method is suitable to determine SalB in plasma and to investigate the pharmacokinetics of SalB.     

Measurement of N-methyl-2-pyridone-5-carboxamide in urine by high performance liquid chromatography

We have previously described a simple and reproducible method for the measurement of nicotinamide and its major metabolite N-methyl-2-pyridone-5-carboxamide (2-pyr) in human plasma. We now describe a low-cost high-throughput method for measurement of urinary 2-pyr, and demonstrate that Isolute C18 bulk can replace use of the column to clean up the samples prior to injection into the HPLC apparatus. Using a standard curve together with an internal standard for each sample, with mean recovery of 2-pyr greater than 95%, the assay has proved reproducible, with considerable savings in cost and time. The principal advantages of this method are the rapid column clean up of samples prior to injection and the simple but effective methodology.     

HPLC determination and pharmacokinetic study of tenatoprazole in dog plasma after oral administration of enteric-coated capsule

A simple, sensitive and selective high-performance liquid chromatographic (HPLC) method with UV detection (306 nm) was developed and validated for determination of tenatoprazole, a novel proton-pump inhibitor, in dog plasma. Tenatoprazole and internal standard (pantoprazole) were extracted into diethyl ether and separated using an isocratic mobile phase of 10 mm phosphate buffer (pH4.7)-acetonitrile (70:30, v/v) on a Diamonsil C(18) column (150 x 4.6 mm, 5 microm). The retention times for tenatoprazole and internal standard were 7.1 and 12.3 min, respectively. No endogenous interferences were observed. This HPLC method was fully validated. The lower limit of quantitation was 20 ng/mL, with a relative standard deviation of less than 20%. A linear range of 0.02-5.0 microg/mL was established. The interday and intraday precisions were within RSD 13.4-10.1 and 4.6-1.4%, respectively. This method developed can be easily applied to the pharmacokinetic study of tenatoprazole in dog plasma after oral administration of an enteric-coated capsule. The plasma concentration of tenatoprazole from six dogs showed a mean C(max) of 2.63 microg/mL at T(max) of 1.89 h. The bioavailability of tenatoprazole was improved by administration of enteric-coated capsule.     

Simultaneous determination of ZLR-8 and its active metabolite diclofenac in dog plasma by high-performance liquid chromatography

ZLR-8 is a nitric oxide releasing derivative of diclofenac for the treatment of inflammation. In this paper, a sensitive and reliable high-performance liquid chromatography method for simultaneous determination of ZLR-8 and its active metabolite diclofenac in the plasma of beagle dogs has been developed and validated. After the addition of ketoprofen as the internal standard (IS), plasma samples were extracted with n-hexane-isopropanol (95:5, v/v) mixture solution and separated by HPLC on a reversed-phase C(18) column with a mobile phase of gradient procedure. Analytes were determined by the UV detector which was set at 280 nm. The method was proved to be sensitive and specific by testing six different plasma batches. Calibration curves of ZLR-8 and diclofenac were linear over the range 0.05-4.0 microg/mL. The within- and between-batch precisions (RSD%) were lower than 10% and accuracy ranged from 85 to 115%. The lower limit of quantification was identifiable and reproducible at 0.05 microg/mL. The proposed method has been readily implemented in preclinical pharmacokinetics studies of ZLR-8 and its active metabolite diclofeance. Representative plasma concentration vs time profiles resulting from administration of ZLR-8 to beagle dogs are presented in this communication.     

Determination of hydroxysafflor yellow A in rat plasma and tissues by high-performance liquid chromatography after oral administration of safflower extract or safflor yellow

A simple and reproducible HPLC method for quantification of hydroxysafflor yellow A (HSYA) in rat plasma and tissues after oral administration of safflower extract or safflor yellow (SY) was developed. Sample preparation was achieved by protein precipitation of plasma and tissue homogenates with three volumes of methanol. p-Hydroxybenzaldehyde was used as the internal standard (IS). HSYA and IS were separated on a Hypersil BDS-C(18) column with a gradient elution system composed of acetonitrile and aqueous acetic acid. UV detection was used at 320 nm. The calibration curves were linear in all matrices (r(2) > 0.999) in the concentration ranges 0.51-101.36 microg/mL for plasma, 12.27-2454.46 microg/g for intestines and 0.96-192.20 microg/g for lung. The intra-day and inter-day precision were all less than 12.5%, and the extract recovery was in the range 64.1-103.7% with RSD less than 15.6% for HSYA in all matrices. The method was used successfully to quantify HSYA in rat plasma and tissue samples to support a pharmacokinectic study.     

柱前衍生高效液相色谱法测定鱼罐头中的组胺

建立了一种测定鱼罐头中组胺含量的柱前衍生高效液相色谱(HPLC)方法。样品匀浆后采用高氯酸水溶液超声提取,提取液经丹酰氯衍生后,采用HPLC分离,紫外检测器检测,外标法定量。采用粒径为1.8 μm固定相填料的C18色谱柱,在0.3 mL/min的流速下,样品的分析时间小于5 min,并可有效地减少流动相消耗,节约成本。组胺在0.08～8.00 mg/L内线性关系良好,相关系数为0.99998;酱煮鲐鱼罐头中组胺在不同浓度水平的平均加标回收率均大于96%,相对标准偏差(RSD)小于2.5%;鱼罐头中组胺的定量限可达5.00 mg/kg。所建立的HPLC方法快速、灵敏度高、重复性好,前处理方法简单,可用于鱼罐头中组胺的测定。     

Analyses of two azo dyes by high-performance liquid chromatography

Two structurally similar azo dyes, Direct Blue No. 6 and Direct Blue No. 15, are analyzed by separate reversed-phase high-performance liquid chromatographic (HPLC) systems utilizing a dual-wavelength UV/visible detector at 254 and 546 nm. Each dye contains more than 35 impurity peaks. Different lots of each dye are compared by means of their respective chromatographic profiles. The system used to obtain a chromatographic profile for each dye is adapted to make comparisons of the major component in different lots by an internal standard method. These methods are reproducible, giving relative standard deviations ranging from approximately 1 to 5%. These HPLC systems are adaptable for the analysis of other structurally similar dyes.     

Spectrophotometric and column high-performance liquid chromatographic methods for simultaneous estimation of metoprolol tartrate and hydrochlorothiazide in tablets

Simple, accurate, economical, and reproducible UV spectrophotometric and column high-performance liquid chromatographic (HPLC) methods were developed for simultaneous estimation of a 2-component drug mixture of metoprolol tartrate and hydrochlorothiazide in combined tablet dosage form. The first method used the simultaneous equation method with 7 mixed standards and the absorption maxima at 223 and 271 nm, respectively, for metoprolol tartrate and hydrochlorothiazide in methanol. Linearity was observed in the concentration ranges of 4-24 and 2-16 microg/mL for metoprolol tartrate and hydrochlorothiazide, respectively. The developed HPLC method used a reversed-phase C18 column and methanol-water (95 + 5) mobile phase at an ambient temperature of 27 +/- 2 degrees C and UV detection at 225 nm; the run time was 10 min, and quantification was based on peak area. The injection repeatability and intraday and interday repeatability were calculated. Paracetamol was used as an internal standard for the HPLC method, and linearity was observed in the concentration range of 5-50 microg/mL for metoprolol and 2-20 microg/mL for hydrochlorothiazide. The proposed methods were successfully applied for the determination of metoprolol tartrate and hydrochlorothiazide in bulk powder and dosage form. The results obtained were analyzed statistically, and there was no significant difference between the 2 methods. The validation was performed according to International Conference on Harmonization guidelines.     

Development and validation of a sensitive quantification method for hematoporphyrin monomethyl ether in plasma using high-performance liquid chromatography with fluorescence detection

A rapid, sensitive, precise and specific method for determination of hematoporphyrin monomethyl ether (HMME), a novel photodynamic therapy (PDT) drug, was developed and validated using high-performance liquid chromatography (HPLC) with fluorescence detection. HMME was isolated from the plasma by a single-step liquid-liquid extraction with ethyl acetate. The analyte and internal standard fluorescein were baseline separated on a Diamonsil C(18) analytical column (4.6 x 150 mm, 5 microm) and analyzed using a fluorescence detector with the excitation and emission wavelengths set at 395 and 613 nm, respectively. The method was linear in the concentration range 0.025-5 microg/mL with a lower limit of quantitation (LLOQ) of 10 ng/mL. The inter- and intra-day accuracies and precisions were all within 10% and the mean recoveries of HMME and fluorescein were 95 +/- 3.7 and 90 +/- 2.3%, respectively. The analyte was stable during all sample storage, preparation and analysis periods. This method was successfully applied to a pharmacokinetic study after a single-dose intravenous administration of HMME (5 mg/kg) to beagle dogs. This method was reproducible and sensitive enough for the pharmacokinetic study of HMME. Based on the results of the pharmacokinetic study, we suggest that a rather long light-avoiding time is essential for patients under HMME therapy.     

Simultaneous determination of three polyphenols in rat plasma after orally administering hawthorn leaves extract by the HPLC method

A simple and sensitive HPLC method was developed to simultaneously determine three active compounds, vitexin-4″-O-glucoside (VG), vitexin-2″-O-rhamnoside (VR) and hyperoside (HP), in rat plasma after administering the hawthorn leaves extract (HLE). An HPLC assay with baicalin as the internal standard was carried out using a Phenomsil C?? analytical column with UV detection at 332?nm. The mobile phase consisted of methanol-acetonitrile-tetrahydrofuran-1% glacial acetic acid (6?:?1.5?:?18.5?:?74, v/v/v/v). The calibration curves were linear over the range of 2.5-500, 0.2-25 and 0.25-12.5?μg?mL?1 for VG, VR and HP, respectively. The method was reproducible and reliable, with relative standard deviations of the intra- and inter-day precision between 1.2% and 13.2% for the analysis of the three analytes. The validated HPLC method herein described was successfully applied to the pharmacokinetic study of VG, VR and HP after oral administration of HLE to rats over the dose range of 2.5-10 mL?kg?1.